Phase 1b/2 Combination Study of the BET Inhibitor ZEN-3694 with the PARP Inhibitor Talazoparib for the Treatment of TNBC Patients without gBRCA1/2 Mutations

Time: 4:00 pm
day: Day Two


• PARP inhibitor activity is limited to tumors with BRCA1 or BRCA2 or PALB2 mutations in TNBC patients
• Preclinical models have shown that BET bromodomain inhibitors sensitize tumors to PARP inhibitors regardless of BRCA status
• ZEN-3694 + talazoparib combination is well tolerated and has shown clinical activity in TNBC patients without germline BRCA1/2 mutations (or PALB2)